Evidence map›Paper›PMID 35776382›Full record

ArticleInfection2023

Diagnostic delay in pulmonary blastomycosis: a case series reflecting a referral center experience.

Aysun Tekin, Yuliya Pinevich, Vitaly Herasevich, Brian W Pickering, Paschalis Vergidis, Ognjen Gajic, John C O'Horo

Open access · greenAbstract read
In one paragraph

Article in Infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Open forum infectious diseases · 2023
    Article
  6. Article
  7. Blastomycosis-Some Progress but Still Much to Learn.Journal of fungi (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Aysun Tekin *Department of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1891-2118
Yuliya Pinevich *Department of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Vitaly HerasevichDepartment of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Brian W PickeringDepartment of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Paschalis VergidisDivision of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA.
Ognjen GajicDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0003-4218-0890
John C O'HoroDivision of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA. ohoro.john@mayo.edu.ORCID http://orcid.org/0000-0002-0880-4498
Mayo Clinic in Arizona · USMayo Clinic · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

purposeThe diagnosis of pulmonary blastomycosis is usually delayed because of its non-specific presentation. We aimed to assess the extent of diagnostic delay in hospitalized patients and detect the step in the diagnostic process that requires the most improvement.

methodsAdult patients diagnosed with pulmonary blastomycosis during a hospital admission between January 2010 through November 2021 were eligible for inclusion. Patients who did not have pulmonary involvement and who were diagnosed before admission were excluded. Demographics and comorbid conditions, specifics of disease presentation, and interventions were evaluated. The timing of the diagnosis, antifungal treatment, and patient outcomes were noted. Descriptive analytical tests were performed.

resultsA total of 43 patients were diagnosed with pulmonary blastomycosis during their admissions. The median age was 47 years, with 13 (30%) females. Of all patients, 29 (67%) had isolated pulmonary infection, while 14 (33%) had disseminated disease, affecting mostly skin and musculoskeletal system. The median duration between the initial symptoms and health care encounters was 4 days, and the time to hospital admission was 9 days. The median duration from the initial symptoms to the diagnosis was 20 days. Forty patients (93%) were treated with empirical antibacterials before a definitive diagnosis was made. In addition, corticosteroid treatment was empirically administered to 15 patients (35%) before the diagnosis, with indications such as suspicion of inflammatory processes or symptom relief. In 38 patients (88%), the first performed fungal diagnostic test was positive. Nineteen patients (44%) required admission to the intensive care unit, and 11 patients (26%) died during their hospital stay.

conclusionThere was a delay in diagnosis of patients with pulmonary blastomycosis, largely attributable to the lack of consideration of the etiological agent. Novel approaches to assist providers in recognizing the illness earlier and trigger evaluation are needed.

Indexed as

BlastomycosisAdultAntifungal AgentsDelayed DiagnosisFemaleHumansIntensive Care UnitsMaleMiddle AgedSkinAntifungal AgentsAdvanced informatics technologyAtypical microorganismsBlastomycosisDiagnostic delayIntelligent alert systems

Identifiers

PMID35776382
PMCPMC10208673
OpenAlexW4283755746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.